IFI30 and Familial prostate cancer: In this review, we propose a framework for including both class I and class II pathways in future prostate cancer immunotherapy through careful selection of tumor Ags, understanding of cysteinylation in epitope modification, and the presence of gamma-interferon-inducible lysosomal thiol reductase (GILT) in tumor Ag processing and presentation.